Radiosensitising agents for the radiotherapy of cancer: Novel molecularly targeted approaches

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 6, 2009, Pages 775-799

  Dumont, Francis ^a   Altmeyer, Anais ^a   Bischoff, Pierre ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Angiogenesis; Apoptosis; Cancer; Cell survival; DNA repair; Intracellular signalling; Kinases; Molecular targets; Radioresistance; Radiosensitiser; Radiotherapy

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; A 641397; A 690002; ABT 263; AEG 35156; AG 14361; AG 14447; BORTEZOMIB; CEP 9722; CHIR 124; CP 466722; ERLOTINIB; GEMCITABINE; GOSSYPOL; GPI 15427; GPI 21016; IC 87361; ISOSORBIDE; KU 0060648; LY 2181308; NELFINAVIR; NU 7441; NUTLIN 3; P 529; PANOBINOSTAT; PF 477736; PRIMA 1; PX 866; RADIOSENSITIZING AGENT; SH 130; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN METASTASIS; CANCER RADIOTHERAPY; CELL GROWTH; CELL SURVIVAL; CYTOTOXICITY; DNA REPAIR; DRUG STRUCTURE; GLIOBLASTOMA; HUMAN; LUNG CANCER; PANCREAS CANCER; PATENT; RADIOSENSITIVITY; REVIEW; SOLID TUMOR;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DNA REPAIR; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATENTS AS TOPIC; RADIATION-SENSITIZING AGENTS;

EID: 67649386894     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902967666     Document Type: Review

References (146)

1. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 2007;19:397-417 (Pubitemid 46995615)
2. Oehler C, Dickinson DJ, Broggini-Tenzer A, et al. Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. Curr Pharm Des 2007;13:519-535 (Pubitemid 46477755)
3. Bischoff P, Altmeyer A, Dumont F. Radiosensitizing agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitizers. Expert Opin Ther Patents 2009;19(5):643-662
4. Jeggo P, Löbrich M. Radiation-induced DNA damage responses. Radiat Prot Dosimetry 2006;122:124-127
5. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007;26:7816-7824 •• Overview of anticancer therapeutic strategies targeting molecular components of DNA strand break repair that may be applicable to tumour radiosensitisation. (Pubitemid 350242461)
6. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204 (Pubitemid 351301852)
7. Cann KL, Hicks GG. Regulation of the cellular DNA double-strand break response. Biochem Cell Biol 2007;85:663-674 (Pubitemid 351198414)
8. Kudos Pharmaceuticals Ltd. Aminopyrones and their use as ATM inhibitors. WO2005016919; 2005
9. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9159 (Pubitemid 39665530)
10. Cowell IG, Durkacz BW, Tilby MJ. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectasia mutated. Biochem Pharmacol 2005;71:13-20 (Pubitemid 41713522)
11. Rainey MD, Charlton ME, Stanton RV, et al. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008;68:7466-74 •• Demonstrates that short-term (4 h or less) pharmacological inhibition of ATM kinase activity at the time of irradiation is sufficient to radiosensitise tumour cells in vitro.
12. Kudos Pharmaceuticals Ltd. ATM inhibitor. WO2007026157; 2007
13. Southern Research Institute. Targeting NBS1-ATM interaction to sensitize cancer cells to radiotherapy and chemotherapy. WO2008054726; 2008
14. Shinohara ET, Geng L, Tan J, et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 2005;65:4987-4992 (Pubitemid 40827302)
15. Kudos Pharmaceuticals Ltd, Cancer Rec Tech Ltd. DNA-PK inhibitors. WO2006109081; 2006
16. Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66:5354-5362 (Pubitemid 43844961)
17. Albertella MR, Slade A, Shea KF, et al. Potent in vitro and in vivo radiosensitisation by the selective DNA-dependent protein kinase inhibitor KU-0060648 [abstract 4080]. Proc Am Assoc Cancer Res 2008;49
18. Kudos Pharmaceuticals Ltd, Cancer Rec Tech Ltd. Use of DNA-PK inhibition to sensitise ATM-deficient cancers to DNA-damaging cancer therapies. WO2006126010; 2006
19. Institut Curie, Centre National de la Recherche Scientifique. Dbait and uses thereof. WO2008034866; 2008
20. Quanz M, Berthault N, Roulin C, et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. Clin Cancer Res 2009;15:1308-1316 •• Demonstrates that short dsDNA molecules (DBaits) that mimic DSBs could inhibit DNA repair after IR exposure and could effectively radiosensitise different types of radioresistant tumours grown as xenografts in mice.
21. Beretta GL, Gatti L, Benedetti V, et al. Small molecules targeting p53 to improve antitumor therapy. Mini Rev Med Chem 2008;8:856-868
22. Janetka JW, Ashwell S, Zabludoff S, et al. Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Dev 2007;10:473-486 •• Reviews the large diversity of chemical inhibitors of Chk1 currently identified and discusses their potential use for sensitising tumours to DNA-damaging agents. (Pubitemid 47093131)
23. Abbott Laboratories. Urea derivatives as kinase inhibitors. EP1534692; 2005
24. Chen Z, Xiao Z, Gu WZ, et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 2006;119:2784-2794 (Pubitemid 44846229)
25. Chiron Corporation. Combination therapy with CHK1 inhibitors. US2005256157; 2005
26. Tao Y, Leteur C, Yang C, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: Effects of p53 and cell cycle checkpoints. Cell Cycle 2009;8:1196-1205
27. Pfizer Inc. Aminopyrazole compounds and use as Chk1 inhibitors. WO2005009435; 2005
28. Cullinane C, Raleigh J, Anderes K, et al. Mechanisms of radiation enhancement by the CHK1 inhibitor PF-477736 [abstract 5386]. Proc Am Assoc Cancer Res 2007;48
29. Clinical Trials. Available from: www.clinicaltrials.gov.
30. Wu W, Wang M, Wu W, et al. Repair of radiation induced DNA double strand breaks by backup NHEJ is enhanced in G2. DNA Repair 2008;7:329-338
31. Weltin D, Holl V, Hyun JW, et al. Effect of 6(5H)-phenanthridinone, a poly (ADP-ribose) polymerase inhibitor, and ionizing radiation on the growth of cultured lymphoma cells. Int J Radiat Biol 1997;72:685-692 (Pubitemid 28020333)
32. Chalmers AJ. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin Oncol (R Coll Radiol) 2004;16:29-39 •• Reviews the role of PARP-1 in the detection and repair of DNA strand breaks and outlines the rationale for therapeutic application of PARP-1 inhibitors in tumour radiosensitisation. (Pubitemid 38195867)
33. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-1388 (Pubitemid 46450426)
34. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67 (Pubitemid 38180960)
35. Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-56 •• Shows that in vitro evaluation of PARP inhibitors needs to be complemented by in vivo xenograft studies to select for the most efficacious compound in terms of its ability to sensitise tumour cells to DNA-damaging therapies, including RT. This screening protocol led to the identification of the phosphate salt of AG14361 (AG014699) as a clinical trial candidate.
36. Pfizer, Cancer Research Technology Ltd. Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor. WO2006033006; 2006
37. Abbott Laboratories. 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors. WO2006110816; 2006
38. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-2737 • Provides experimental evidence that ABT-888 potentiated the antitumour effect of IR in a colon carcinoma xenograft model. (Pubitemid 46795129)
39. Liu SK, Coackley C, Krause M, et al. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008;88:258-68 •• Shows that ABT-888 was able to radiosensitise human prostate and lung cancer cell lines under condition of acute hypoxia in vitro.
40. Abbott Laboratories. Combination therapy with PARP inhibitors. WO2007084532; 2007
41. MGI GP Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP. US2008058325; 2008
42. Russo AL, Kwon HC, Burgan WE, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009;15:607-612
43. Cephalon Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent. WO2008063644; 2008
44. Burd R, Limesand K, Lavorgna S, et al. The selective PARP inhibitor, CEP-9722, exhibits significant radiosensitization against radioresistant U87 human glioblastoma xenografts and does not potentiate radiation-induced normal tissue toxicity [abstract 42114]. Proc Am Assoc Cancer Res 2008;49
45. Bianco R, Gelardi T, Damiano V, et al. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007;39:1416-1431 (Pubitemid 47031050)
46. Valerie K, Yacoub A, Hagan MP, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007;6:789-801 •• This review summarises the current knowledge on the mechanisms through which IR can activate EGFR and other TK receptors, leading to activation of cytoprotective downstream signalling pathways that mediate apoptosis inhibition and tumour cell survival/ proliferation. (Pubitemid 46554549)
47. Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007;13:6555-6560 •• Discusses the evidence that IR induces the nuclear translocation of EGFR and its interaction with DNA-PK, thereby promoting the repair of IR-induced DNA damage. (Pubitemid 350206788)
48. Rodemann HP, Dittmann K, Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 2007;83:781-791
49. Baumann M, Krause M, Dikomey E, et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007;83:238-248 • Reviews preclinical data suggesting that antibody-mediated blockade of EGFR is more efficient at enhancing local tumour control by fractionated RT than is the targeting of EGFR TK activity by a chemical inhibitor. (Pubitemid 46915540)
50. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578 (Pubitemid 43209104)
51. Harari PM, Chinnaiyan P. Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor. WO2006110176; 2006
52. Magné N, Chargari C, Castadot P, et al. The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. Eur J Cancer 2008;44:2133-2143
53. Piperdi B. Combined treatment with bortezomib and an epidermal growth factor receptor inhibitor. WO2006110175; 2006
54. LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008;11:32-50
55. OSI Pharmaceuticals Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors. WO2007106503; 2007
56. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-4711
57. Boehringer Ingelheim Int, Boehringer Ingelheim Pharmaceuticals. Combination treatment of cancer comprising EGFR/ HER2 inhibitors. WO2007054551; 2007
58. Schütze C, Dörfler A, Eicheler W, et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 2007;183:256-264 (Pubitemid 46725991)
59. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9:288-296 (Pubitemid 351722948)
60. Prolx Pharmaceuticals Corp, University of Arizona, University of Pittsburgh. Wortmannin analogs and methods of using same in combination with chemotherapeutic agents. WO2007008200; 2007
61. Hayakawa M, Kaizawa H, Morimoto H, et al. Fused heterolaryl derivatives. US7173029; 2007
62. Prevo R, Deutsch E, Sampson O, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008;68:5915-5923 •• Demonstrates that the PI3K inhibitor, PI-103, could sensitise various tumour cell lines to the cytotoxicity of IR by increasing the persistence of IR-induced DNA damage.
63. Chen JS, Zhou LJ, Entin-Meer M, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther 2008;7:841-850 •• Shows that PI-103 could enhance the antitumour effect of IR against glioblastoma xenografts. (Pubitemid 351551037)
64. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009;8:1-9
65. Fujiwara K, Iwado E, Mills GB, et al. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 2007;31:753-760
66. Toulany M, Kehlbach R, Florczak U, et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 2008;7:1772-1781
67. Paloma Pharmaceuticals, Inc. Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis. WO2007133249; 2007
68. Diaz R, Nguewa PA, Diaz-Gonzalez JA, et al. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br J Cancer 2009;100:932-40 •• Shows that P529 potentiated IR-induced growth arrest in an aggressive prostate cancer cell line mainly through AKT inhibition and enhanced the antitumour effect of RT in vivo by reducing proliferation and promoting apoptosis.
69. Trustees of the University of Pennsylvania. The use of nelfinavir as a radiation sensitizer. WO2006044808; 2006
70. Plastaras JP, Vapiwala N, Ahmed MS, et al. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 2008;7:628-635 (Pubitemid 351846994)
71. Albert JM, Kim KW, Cao C, et al. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006;5:1183-1189 (Pubitemid 43881310)
72. Murphy JD, Spalding AC, Somnay YR, et al. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 2009;15:589-596
73. Ahmed KM, Li JJ. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 2008;44:1-13 • This review discusses the role of NF-kB in mediating tumour radioresistance and how activation of this transcription factor by IR leads to NF-kB activation. Key elements within the NF-kB prosurvival network may thus represent novel targets for radiosensitisation of tumour cells. (Pubitemid 350138635)
74. Georgetown University. The p65 subunit of NF-KB for the radiosensitization of cells US2005287158; 2005
75. University of California. DHMEQ as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells. WO2006060819; 2006
76. Sun Y, St Clair DK, Fang F, et al. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 2007;6:2477-2486 (Pubitemid 47480413)
77. Tamatani T, Azuma M, Motegi K, et al. Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells. Int J Oncol 2007;31:761-768
78. Xu Y, Fang F, St Clair DK, et al. SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 2008;7:2367-76 • Shows that a cell permeable peptide (SN52) could inhibit IR-induced NF-kB activation and radiosensitise prostate a clinically relevant IR doses in vitro.
79. Lee DF, Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 2008;14:5656-5662
80. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008;9:1002-1011 •• Provides an overview of the mechanisms through which tumour cells may elude apoptosis and of the various molecular components of these mechanisms that may serve as targets for enhancing IR-induced apoptosis.
81. Aprea AB. 1-Azabicyclo [2,2,2] octan-3-one derivatives. US2005090540; 2005
82. Supiot S, Zhao H, Wiman K, et al. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 2008;86:407-11 •• Shows that PRIMA-1met could radiosensitise p53-deficient prostate cancer cells under both normoxic and hypoxic conditions in vitro.
83. Hoffmann La Roche. Novel cis-imidazolines. WO2005110996; 2005
84. Cao C, Shinohara ET, Subhawong TK, et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 2006;5:411-417
85. Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008;7:993-999 •• Similar to PRIMA-1met, Nutlin-3 could radiosensitise prostate cancer cells under both normoxia and hypoxia independently of their p53 status. (Pubitemid 351551053)
86. An J, Chervin AS, Nie A, et al. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 2007;26:652-661 •• Demonstrates that treatment of radioresistant prostate cancer cells with a minimally cytotoxic concentration of the Bcl-2 inhibitor HA14-1 markedly enhanced their apoptotic response to IR, regardless of their p53 status.
87. University of Michigan, University of Georgetown Medical Center. Small molecule antagonists of Bcl-2 family proteins. WO2005069771; 2005
88. Abbott Laboratories. Apoptosis promoters. WO2006127364; 2006
89. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681 (Pubitemid 40825512)
90. AVI Biopharma Inc. Method and antisense compound for potentiating anti-cancer agents. WO2005047465; 2005
91. Aegera Therapeutics Inc. Antisense IAP nucleobase oligomers and uses thereof. US7091333; 2006
92. Giagkousiklidis S, Vellanki SH, Debatin KM, et al. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007;26:7006-7016 (Pubitemid 350014607)
93. Ohnishi K, Nagata Y, Takahashi A, et al. Effective enhancement of X-ray-induced apoptosis in human cancer cells with mutated p53 by siRNA targeting XIAP. Oncol Rep 2008;20:57-61
94. University of Michigan. Smac peptidomimetics and uses thereof. WO2005069888; 2005
95. University of Michigan. Conformationally constrained Smac mimetics and the uses thereof. WO2006010118; 2006
96. Dai Y, Liu M, Tang W, et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res 2008; 14:7701-7710 •• Shows that the IAP antagonist SH-130 markedly enhanced IR-induced apoptosis in radioresistant prostate cancer cells overexpressing IAP and potently radiosensitised the same cells grown as xenografts in mice without increasing systemic toxicity.
97. Burnham Institute, Torrey Pines Institute for Molecular Studies. Methods and compositions for derepression of IAP-inhibited caspase. US20050119176; 2005
98. Karikari CA, Roy I, Tryggestad E, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007;6:957-66 • Demonstrates that an XIAP antagonist (1396-11) could synergise with IR in markedly reducing the clonogenic survival of pancreatic cancer cells in vitro.
99. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70
100. Capalbo G, Rödel C, Stauber RH, et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007;183:593-599 • This review discusses the rationale for targeting survivin as a strategy to improve the effectiveness of RT in the treatment of cancer.
101. Isis Pharmaceuticals Inc, Eli Lilly Co. Modulation of survivin expression. WO2005002507; 2005
102. Rödel F, Frey B, Leitmann W, et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71:247-255 •• Demonstrates that antisense oligonucleotide- mediated inhibition of survivin expression could augment IR-induced apoptosis and tumour growth delay in colorectal carcinoma cells.
103. Santaris Pharma AS. LNA oligonucleotides and the treatment of cancer. WO2006050732; 2006
104. Yamanouchi Pharma Co Ltd. Fused imidazolium derivatives. US6734203; 2004
105. Iwasa T, Okamoto I, Suzuki M, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008;14:6496-6504 •• Shows that YM155 could down-regulate the expression of survivin and enhance synergistically IR-induced apoptosis in lung cancer cells. YM155 also potentiated the tumour growth delay caused by RT in lung cancer xenografts.
106. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-5542 (Pubitemid 47255934)
107. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Invest Drugs 2007;16:659-678 (Pubitemid 46729100)
108. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25:4051-6 • Reviews the preclinical evidence indicating that HDAC inhibitors from structurally diverse classes can enhance both the in vitro and in vivo radiosensitivity of various types of human tumour cell lines.
109. Georgetown University. Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy US2005222013; 2005
110. Sloan Kettering Institute for Cancer Research. Combination therapy for the treatment of cancer. EP1501489; 2005
111. Novartis Pharmaceuticals GMBH. Combination of histone deacetylase inhibitors and radiation. WO2007050655; 2007
112. Geng L, Cuneo KC, Fu A, et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006;66:11298-304 •• Shows that pretreatment of lung cancer cells with LBH589 increased the persistence of DSBs and the level apoptosis induced by IR and potentiated the antitumour effect of IR in vivo in a synergistic manner. (Pubitemid 46009960)
113. Kim IA, Shin JH, Kim IH, et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 2006;12:940-949 (Pubitemid 43259877)
114. Georgetown University. Isoform-selective HDAC inhibitors. WO2008019025; 2008
115. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007;13:1625-1629 (Pubitemid 46952925)
116. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-453
117. Camphausen K, Tofilon PJ. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 2007;13:4326-4330 •• This paper outlines the rationale for inhibiting Hsp90 as a multitarget radiosensitisation method, based on the evidence that a number of Hsp90 client proteins contribute to tumour cell radioresistance, and summarises preclinical data indicating that Hsp90 blockade compromises the repair of IR-induced DNA damage in tumour cells without affecting the radiosensitivity of normal fibroblasts. (Pubitemid 47219695)
118. Van Andel Research Institute. Geldanamycin and derivatives inhibit cancer invasion and identify novel targets. WO2005095347; 2005
119. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009;17:2225-2235
120. Sloan-Kettering Institute for Cancer Research. Small-molecule Hsp90 inhibitors. WO2006084030; 2006
121. Patterson DM, Rustin GJ. Vascular damaging agents. Clin Oncol (R Coll Radiol) 2007;19:443-456 • Reviews the current approaches for targeting the tumour vasculature, comprising angiogenesis inhibitors and vascular disrupting agents, which may be utilised to potentiate the efficacy of RT. (Pubitemid 46995617)
122. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res 2008;100:113-131 (Pubitemid 351932181)
123. Shannon AM, Williams KJ. Antiangiogenics and radiotherapy. J Pharm Pharmacol 2008;60:1029-1036 •• Discusses the rationale for targeting the tumour vasculature with antiangiogenic agents to sensitise endothelial cells to the effect of IR and paradoxically increase tumour oxygenation, and thereby enhance the efficacy of RT.
124. Roskoski RJ. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213 (Pubitemid 46679285)
125. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007;26:281-290
126. Brieger J, Kattwinkel J, Berres M, et al. Impact of vascular endothelial growth factor release on radiation resistance. Oncol Rep 2007;18:1597-1601
127. Regeneron Pharmaceuticals. Use of a VEGF antagonist in combination with radiation therapy. WO2005016369; 2005
128. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol Phys 2007;67:1526-1537 (Pubitemid 46467151)
129. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13:3397-3402 •• Shows that anginex and bevacizumab were both capable of increasing the oxygenation of tumour xenografts during the first 4 days of treatment and that such a transient effect enhanced the antitumour activity of single dose or fractionated RT in mice. (Pubitemid 46944928)
130. Williams KJ, Telfer BA, Shannon AM, et al. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 2007;6:599-606 •• Shows that cediranib (AZD2171) could enhance the RT response of human tumour xenografts independently of whether the compound was administered concomitantly or sequentially with IR. (Pubitemid 46332462)
131. Astrazeneca AB. Combination of ZD6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer. EP1534287; 2005
132. Shibuya K, Komaki R, Shintani T, et al. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;69:1534-1543 •• The dual inhibitor of VEGFR and EGFR, ZD6474 (Vandetanib) blocked pleural effusion formation and angiogenesis and enhanced the antivascular and antitumour effects of RT in an orthotopic human lung cancer model in mice. (Pubitemid 350116420)
133. Oehler-Jänne C, Jochum W, Riesterer O, et al. Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models. Mol Cancer Ther 2007;6:2496-2504 (Pubitemid 47480415)
134. Bozec A, Sudaka A, Fischel JL, et al. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008;99:93-99 (Pubitemid 351920227)
135. Vanderbilt University. PI3K antagonists as radiosensitizers. US2006084697; 2006
136. Toyo Suisan Kaisha. Radiosensitizer. EP1734046; 2006
137. Sakimoto I, Ohta K, Yamazaki T, et al. Alpha-sulfoquinovosylmonoacyl- glycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer Res 2006;66:2287-2295 (Pubitemid 43294942)
138. Mori Y, Sahara H, Matsumoto K, et al. Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3'-sulfoquinovosyl-1'- monoacylglycerol, targeting angiogenesis. Cancer Sci 2008;99:1063-1070 (Pubitemid 351997613)
139. University of Minnesota. Tumor treatment using beta-sheet peptides and radiotherapy. CA2528635; 2007
140. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006;103:15975-15980 (Pubitemid 44657577)
141. Dings RP, Williams BW, Song CW, et al. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 2005;115:312-319 (Pubitemid 40586743)
142. National Institute of Radiological Sciences, Kringle Pharmaceuticals Inc. Radiotherapy enhancing agent in radiotherapy for tumor. WO2007091681; 2007
143. Matsumoto K, Nakamura T, Sakai K, et al. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics 2008;8:3360-3370
144. Uto Y, Nagasawa H, Jin CZ, et al. Design of antiangiogenic hypoxic cell radiosensitizers: 2-Nitroimidazoles containing a 2-aminomethylene-4- cyclopentene-1,3-dione moiety. Bioorg Med Chem 2008;16:6042-6053 •• Provides an example of rationally designed bifunctional agent incorporating a 2-nitroimidazole moiety and a TK inhibitory group, which may prove useful as an antiangiogenic hypoxic cell tumour radiosensitiser for RT enhancement. (Pubitemid 351758833)
145. Bristow RG, Hill RP. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-192
146. Hamada N. Recent insights into the biological action of heavy-ion radiation. J Radiat Res (Tokyo) 2009;50:1-9